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1. Introduction
Epilepsy impacts the pharmacotherapeutic management of
patients with dementia with Lewy bodies (DLB) in two non-
exclusive ways: first, epilepsy makes less easy the use of the
symptomatic treatments of the disease (Figure 1); second,
the prescription of antiepileptic drugs (AEDs) in these
patients carries a substantial risk of clinical aggravation
(Table 1). Such considerations are not theoretical because
DLB is a common etiology (the second or third) of cognitive
decline and dementia in neuropathological studies: It is
now recognized as an important cause of neurocognitive
disorder affecting 10–15% of patients [1]. Depending on the
clinical stage of the disease, DLB patients are commonly ≥
70 years old in the prodromal phase (mild cognitive impair-
ment due to DLB) and are logically older in the dementia
stage [2]. Thus, DLB concerns older patients with non-
neurological (cardiovascular diseases, renal insufficiency,
endocrine disorders, etc.) and neurological comorbidities
(in particular stroke and traumatic brain injury) [3]. As
early as in the prodromal phase, DLB is characterized by
aberrant hyperexcitability manifested by common myoclo-
nus and electroencephalographic (EEG) abnormalities [4,5].
The explanation is not completely clear but fundamental
data have underpinned the fact that aggregated alpha-
synuclein, the major component of Lewy bodies, is epilep-
togenic by inducing hyperexcitability in affected neurons
(whether cortical or subcortical) [4]. Additionally, DLB is
commonly accompanied by Alzheimer’s disease (AD) co-
pathology, which is furthermore epileptogenic [1,6].
Unsurprisingly, in this context, DLB is associated with inter-
ictal epileptiform discharges on EEG, seizures, and epilepsy
in a substantial proportion of cases (at least 10% according
to present knowledge) [4]. Therefore, the treatment of sei-
zures and/or epilepsy in these patients is a frequent issue in
clinical practice that requires a minimal conceptual frame-
work to avoid mistreatment and/or cognitive-behavioral
aggravation due to inappropriate medications.
2. DLB, relevant clinical–radiological description,
and standard therapeutics
Seizures and epilepsy reported in DLB aremainly focal aware, focal
with impaired awareness, or secondarily generalized. Primary gen-
eralized tonic-clonic seizures (PGTC) are also encountered in DLB
[4]. Thus, AEDs effective in focal seizures and/or PGTC may poten-
tially be useful in such cases, with a particular interest for wide-
spectrum molecules such as levetiracetam (LEV), brivaracetam
(BRV), benzodiazepines (BDZ) and other GABAergics, valproate
(VPA), topiramate (TPM), zonisamide (ZNS), and perampanel
(PER). On the other hand, seizure-specific treatment such as etho-
suximide, stiripentol, or rufinamide should not be considered for
epileptic DLB patients. Before going further into the use of AEDs in
DLB, it is important to bear in mind the core clinical picture of the
disease (in the prodromal or the dementia stage) that allows for an
appropriate diagnosis when used with related criteria [7]. Most of
all, DLB is a neurocognitive disorder: It manifests primarily as cogni-
tive decline with particularly common psychiatric comorbidities
(depression, psychosis) and spontaneous or provoked delirium [7].
In combination with such psycho-cognitive signs and symptoms,
DLB is defined by the occurrence of at least one of the following:
parkinsonism, fluctuations of cognition and/or vigilance, sleep
disturbances, and visual hallucinations. It must be noted that
excessive daytime sleepiness, dysautonomia (i.e., constipation,
orthostatic hypotension), and falls are also very common in DLB.
Additionally, the disease is characterized by mild cerebral atrophy
with a specific pattern in the prodromal phase (affecting the limbic
structures predominantly and the insula in particular) [8]. The
symptomatic treatment of DLB requires non-pharmacological
approaches that are not within the scope of this paper [9]. On
the other hand, the following pharmacotherapeutic options are
indicated: cholinesterase inhibitors (ChEI; i.e., rivastigmine or done-
pezil) for cognitive decline and/or hallucinations, L-DOPA for par-
kinsonism, atypical neuroleptics or pimavanserin for hallucinations
and/or psychosis, specific serotonin uptake inhibitors (SSRI) for
depression and/or agitation, and melatonin or clonazepam for
REM-sleep behavior disorder [10]. If DLB patients have concomi-
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tant epilepsy, some treatments may interact with such comorbid-
ity: SSRI and neuroleptics are potentially ‘epileptogenic’, ChEI and
memantine are sometimes suspected so (but not on a clear and
demonstrated basis) [11–13]. Therefore, when epilepsy is sus-
pected in DLB, their prescription must consider the related risk of
seizure aggravation and should follow the initiation of an appro-
priate AED.
3. Treating epilepsy in DLB: what is the appropriate
AED?
The goal of the treatment is to ensure effectiveness in seizures
with a lower impact on frail DLB patients. At present, no
relevant trial has evaluated AEDs in DLB. Available data
come from very few papers and, in fact, we must admit that
no evidence-based AED(s) have been identified for DLB.
Nonetheless, given the clinical semiology of seizures, drugs
active in focal and tonic-clonic generalized seizures are most
probably useful for treating epilepsy in DLB (see § 2). With
regard to the old age of DLB patients, some general recom-
mendations can be made, as for AD patients [14]. First, the
prescribed doses of AEDs should be low at initiation and
slowly increased (if necessary) to minimize the risk of side
effects, which is, moreover, aggravated by the frequent
decreased renal clearance, by the common lower fluid com-
partment in the body, and/or by low albuminemia in older
patients. Second, the multifactorial risk of bone fracture
(related to osteoporosis, gait and balance impairment, visuos-
patial deficits, etc.) can be significantly worsened by the fol-
lowing AEDs: phenobarbital (PB), carbamazepine (CBZ),
phenytoin (PHT), valproate (VPA), oxcarbazepine (OXC), esli-
carbazepine (ESL), and topiramate (TPM). Third, dyslipidemia
can be favored by CBZ and OXC and have a significant impact
on the progression of the disease by increasing the cerebral
vascular burden. Fourth, DLB subjects often receive antide-
pressants that may pharmacologically interact with AEDs and
alter their effectiveness. Fifth, enzyme-inducing (i.e., PB, CBZ,
PHT, OXC, ESL, and PER) or -inhibiting (i.e., VPA and PER) AEDs
may increase the risk of drug–drug interactions with donepe-
zil, cardiovascular medications, etc. Regarding the key impor-
tance of cognitive impairment in DLB, the AEDs used should
avoid any psycho-cognitive impact. In this regard, GABAergics
(i.e., PB, BDZ, vigabatrin [VGB], tiagabine [TGB], and primidone
[PRM]) are not recommended, and neither are anticholinergic
AEDs (i.e. CBZ, OXC, and ESL) that have the potential to
impede the effect of ChEI. From a cognitive point of view,
VPA should be avoided because it may exacerbate cognitive
decline and the atrophy rate owing to the frequent
underlying AD pathology combined with DLB [1,14].
Moreover, depression can be exacerbated by GABAergics
(i.e., VGB, TGB, PB, PRM), TPM, ZNS, LEV, and BRV, and
Figure 1. Treatments of ictal and interictal features of DLB and their related risks.
Table 1. Clinical features of DLB and related potentially harmful antiepileptic
medications.
Clinical feature of DLB Potentially aggravating AEDs
Cognitive decline CBZ, OXC, ESL; GABAergics; TPM, ZNS, VPA
Depression LEV, BRV, TPM, ZNS, GABAergics





Visual hallucinations TPM, ZNS, GBP, PGB, PER
Excessive daytime
sleepiness
GABAergics, CBZ, OXC, ESL, GBP, PGB
Myoclonus LTG, CBZ, PHT, OXC, GBP, PGB




TPM, ZNS (du to diuretic effect)
Syncopes LCS
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psychosis by VGB, LEV, BRV, TPM, and ZNS. Furthermore, AEDs
can be harmful by aggravating other features of DLB (Table 1).
4. Expert opinion
In view of all the aforementioned considerations (see also
Table 1), few molecules are finally appropriate given the risk
of their neurological and non-neurological impact. It is rea-
sonable to conceive that the best AEDs available for treat-
ing epilepsy in DLB are ‘new AEDs’ developed after the
1990s that carry a lower risk of drug interactions and
enzyme induction/inhibition [14]. Thus, the following appear
legitimately suitable for epileptic DLB patients: low to mod-
erate doses of LTG, LCS, LEV or BRV as first-line treatment,
and low dose of gabapentin (GBP) or pregabalin (PGB)
as second-line treatment. Even with these, however, close
monitoring is required to avoid neuropsychiatric side effects
(Table 1) and aggravation of the vicious circle due to iatro-
genic impact and pharmacological interactions (Figure 1).
But, having posited this, much remains to be done at pre-
sent. On the basis of appropriate trials, we have to establish
which of these five candidate molecules are more relevant
for the treatment of epilepsy in DLB. This will not be an
easy task. The reason lies in the fact that the diagnosis of
epilepsy is particularly challenging in DLB. In fact, the cog-
nitive decline of patients includes an early and peculiar
‘insular’ impairment that hinders an accurate analysis of
interoceptive and exteroceptive perceptions in conjunction
with memory deficits [15]. Consequently, patients are not
always reliable for remembering and describing subjective
ictal semiology and/or for warning when fits or spells occur.
Additionally, focal seizures may be confused with cognitive
fluctuations and therefore be mistaken as a cardinal sign of
the disease instead of suggesting epilepsy work-up. Finally,
when such work-up is carried out, EEG abnormalities may
not be of epileptic origin but rather from background
rhythm alterations related to the disease [16]. For all these
reasons, further work is certainly needed to reliably identify
epileptic DLB patients and to evaluate their ictal and inter-
ictal response to selected AEDs. Inspired by Cumbo et al.
[17], a prospective, randomized, two- or three-arm parallel-
group, case–control study would improve our knowledge in
this field.
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